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Abstract  Conventional  imaging  techniques  cannot  provide  information  about  tissue  mechani-
cal properties.  Many  injuries  can  cause  changes  in  tissue  stiffness,  especially  tumors  and  ﬁbrosis.
In recent  years,  various  non-invasive  ultrasound  methods  have  been  developed  to  study  tissue
elasticity for  a  large  number  of  applications  (breast,  thyroid,  prostate,  kidneys,  blood  vessels,
liver. .  .).  For  non-invasive  assessment  of  liver  diseases,  several  ultrasound  elastography  tech-
niques have  been  investigated:  Transient  elastography  (the  most  extensively  used),  Real  Time
Elastography  (RTE),  Acoustic  Radiation  Force  Impulse  Imaging  (ARFI)  and  more  recently  Shear
Wave Elastography  (SWE).  Even  if  evaluation  of  liver  ﬁbrosis  in  chronic  liver  disease  remains  the
principal application,  there  are  many  others  applications  for  liver:  predicting  cirrhosis-related
complications;  monitoring  antiviral  treatments  in  chronic  viral  liver  disease;  characterizing
liver tumors;  monitoring  local  treatments,  etc.  The  aim  of  this  article  is  to  report  on  the  dif-
ferent hepatic  ultrasound  elastography  techniques,  their  advantages  and  disadvantages,  their
diagnostic accuracy,  their  applications  in  clinical  practice.
© 2013  Éditions  françaises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
IntroductionUltrasound  imaging  plays  a  major  role  in  the  diagnosis,  monitoring  and  therapeutic  deci-
sions  of  chronic  liver  diseases.  It  has  many  clinical  indications:  morphological  examination
of  the  liver  parenchyma  and  assessment  of  the  risk  of  chronic  liver  disease  by  investigating
Abbreviations: A2M, Alpha-2 macroglobulin; ALP, Alkaline phosphatase; ALT, Alanine aminotransferase; APRI:, Aspartate to platelet
ratio index [ratio of ALT (expressed as ‘‘number of times the upper limit of normal’’) × 100/platelets (109/L)]; ARFI, Acoustic Radiation
Force Impulse Imaging; AST, Aspartate aminotransferase; AUROC, Area under the ROC curve (receiver operating characteristic curve);
CPAM, French National Health Insurance system; FNH, Focal nodular hyperplasia; FS, FibroScan®; GGT, Gamma glutamyltranspeptidase;
HA, Hyaluronic acid; HAS, French National Health Authority; HCC, Hepatocellular carcinoma; LB, Liver biopsy; NAFLD, non-alcoholic fatty
liver disease; NASH, Non-alcoholic steatohepatitis; NPV, Negative predictive value; OV, Oesophageal varices; PH, Portal hypertension; PPV,
Positive predictive value; PT, Prothrombin time; ROI, Region of interest; RTE, Real Time Elastography; Se, Sensitivity; Sp:, Speciﬁcity; SWE,
Shear Wave Elastography; US, Ultrasound.
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or  signs  of  dysmorphism  and/or  portal  hypertension;
etecting  and  characterizing  liver  lesions;  monitoring  local
reatments  (such  as  percutaneous  radiofrequency)  and
ssessment  of  treatment  response.
Conventional  imaging  techniques  do  not  provide  informa-
ion  on  tissue  mechanical  properties  although  its  stiffness
ay  vary  considerably.  In  addition,  many  diseases  can  lead
o  changes  in  tissue  stiffness:  tumors  (particularly  malig-
ant)  are  generally  stiffer  than  the  normal  surrounding
issue;  ﬁbrosis  also  causes  a  change  in  the  organ  stiffness
liver-kidney).
Liver  ﬁbrosis  is  a  common  pathway  for  several  liver
njuries.  Viral  (hepatitis  B  virus  (HBV),  hepatitis  C
irus  (HCV),  human  immunodeﬁciency  virus  (HIV)-HCV
o-infection),  autoimmune,  hereditary,  metabolic  and
oxin-mediated  liver  disease  can  result  in  hepatocellular
ysfunction,  expansion  of  extracellular  matrix  with  distor-
ion  of  hepatic  architecture,  portal  hypertension  and  ﬁnally
iver  cirrhosis.  Approximately  20  to  30%  of  patients  with
hronic  liver  disease  develop  cirrhosis.  The  incidence  of
irrhosis  is  increasing  due  to  the  development  of  chronic
epatitis  C,  non-alcoholic  fatty  liver  disease  (NAFLD)  and
ore  speciﬁcally  non-alcoholic  steato-hepatitis  (NASH);  the
atter  one  affecting  almost  3%  of  the  population  in  western
ountries.  Liver  ﬁbrosis  is  therefore  a  major  public  health
roblem.
Different  levels  of  ﬁbrosis  exist  which  in  practice  are
ssessed  using  a  histological  score.  The  most  widely  used  is
he  METAVIR  score,  which  incorporates  ﬁve  stages  of  ﬁbrosis:
0  (no  ﬁbrosis),  F1  (portal  ﬁbrosis  without  septa:  minimal
brosis),  F2  (portal  ﬁbrosis  with  a  few  septa:  moderate  ﬁbro-
is  or  clinically  signiﬁcant  ﬁbrosis),  F3  (septal  ﬁbrosis  with
any  septa  but  no  cirrhosis:  severe  ﬁbrosis)  and  F4  (cirrho-
is).
Staging  liver  ﬁbrosis  in  patients  with  chronic  liver  disease
s  essential  for  patient  management  as  it  allows:
ﬁrstly  to  identify  the  severity  of  the  liver  damage  in  order
to  decide  whether  or  not  to  start  treatment  (chronic  viral
liver  disease)  to  avoid  progression  to  cirrhosis  when  the
ﬁbrosis  becomes  signiﬁcant  (≥  F2);
secondly  to  assess  the  progression  or  regression  of  liver
ﬁbrosis  during  treatment;
lastly  to  institute  speciﬁc  monitoring  to  screen  for
and  treat  complications  (HCC,  oesophageal  varices)  in
patients  suffering  from  cirrhosis  and  even  severe  ﬁbrosis
(≥  F3).
Conventional  ultrasound  cannot  differentiate  accurately
he  different  liver  ﬁbrosis  stages.  Existing  tools  to  assess
iver  ﬁbrosis  include  liver  biopsy  (LB),  which  is  invasive,  and
ther  non-invasive  methods.
Up  to  recently,  LB  has  been  considered  as  the  gold
tandard  to  assess  activity  and  ﬁbrosis  in  patients  with
hronic  liver  disease,  and  is  still  the  reference  method  for
ssessing  ﬁbrosis.  It  can  also  be  used  to  investigate  the
ause  of  liver  disease  and/or  to  assess  other  possible  causes
f  concomitant  liver  disease.  Despite  its  diagnostic  util-
ty,  LB  has  several  limitations,  including  patient  reluctance,
dverse  events,  accessibility,  effective  cost,  sampling  error,
nd  intra-  and  inter-observer  variability.  Moreover,  consid-
ring  the  fact  that  ﬁbrosis  is  heterogeneously  distributed
n  the  liver,  liver  biopsy  has  been  criticized  because  it
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valuates  only  1/50,000  of  the  total  volume  of  the  liver,
ue  to  the  small  volume  of  the  tissue.  For  these  reasons  this
echnique  is  becoming  increasingly  challenged.  As  a  result,
on-invasive  techniques  for  liver  ﬁbrosis  assessment  have
een  widely  developed  in  clinical  practice.
To  assess  liver  ﬁbrosis,  two  types  of  non-invasive  methods
xist  [1]:
the  ﬁrst  one  is  based  on  blood  serum  markers.  Single
blood  marker  (such  as  hyaluronic  acid)  or  an  indirect
‘‘score’’  derived  from  a  combination  of  blood  markers
can  be  used.  While  single  markers  exhibit  insufﬁcient  sen-
sitivity  and  speciﬁcity  for  ﬁbrosis  staging,  indirect  scores
beneﬁt  from  added  diagnostic  values  of  each  marker  and
have  sufﬁcient  diagnostic  performance  to  avoid  a  number
of  biopsies.  The  three  most  widely  used  tests  approved
by  the  HAS  in  speciﬁc  indications  are  the  Fibrotest® [2],
Hépascore® [3]  and  Fibromètre® [4],  which  use  differ-
ent  combinations  of  blood  serum  markers  indices.  These
different  markers  and  their  diagnostic  performance  are
listed  in  Table  1  [1—6];
the  second  one  is  based  on  a  physical  parameter  that
measures  the  tissue  elasticity  and  is  called  elastography.
Elastography  techniques  include  transient  elastography
(FibroScan®),  ARFI,  Real  Time  Elastography,  Shear  Wave
mode  elastography  and  elasto-MR.  Elastography  can
replace  subjective  palpation  and  is  intended  to  image
the  mechanical  properties  of  tissues  and  more  particu-
larly  their  stiffness.  Tissue  stiffness  is  described  by  the
Young  modulus  expressed  in  kilopascals  (E  =  3C2).  The
elastography  methods  are  based  on  a  common  approach:
measurement  of  deformation  induced  in  a  tissue  by  a
force.
Elastography  is  therefore  an  application,  which  produces
he  force  coupled  with  a  measurement  system  for  the  defor-
ities  caused  by  the  force.  There  are  several  types  of  forces
r  applications:
static  compression  induced  externally  by  manual
compression  or  internally  by  organ  motion  (heart,  vessel,
breathing);
dynamic  compression  induced  with  a  continuous  vibration
at  a  given  frequency;
impulse  compression  (transient  vibration):  induced  exter-
nally  by  a  transient  mechanical  impulse  (FibroScan®)  or
internally  by  an  ultrasound  impulse  (ARFI,  SWE),  both
compression  types  producing  shear  waves.
The  aim  of  this  article  is  to  review  the  different
ltrasound  elastography  techniques,  their  advantages  and
imitations,  their  diagnostic  accuracy,  and  their  applications
n  clinical  practice  for  liver  applications.
he different ultrasound elastography
echniques
mpulse elastographyhis  technique  uses  an  external  mechanical  device
FibroScan®) or  an  internal  acoustic  radiation  force  (ARFI
nd  SWE)  to  induce  shear  waves  in  the  tissue  to  be  explored
Table  2).  Shear  wave  propagation  velocity  (Vs)  is  then
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Table  1  Characteristics  and  diagnostic  performance  of  the  main  indirect  blood  serum  markers  to  assess  liver  ﬁbrosis,
which  can  be  used  in  clinical  practice.
Tests  Variables  Disease  Diagnostic
objective
Performance
(AUROC)
APRI  [5]  AST,  platelets HCV F2 0.76/0.80
F4  0.82/0.89
Fib4  [6]  Age,  AST,  ALT,  platelets  HIV-HCV  F2  0.76—0.85
Fibrotest  [2] A2M,  GGT,  haptoglobin,  apoA1,
total  bilirubin
HCV F2 0.78/0.85
F4  0.89—0.92
Hépascore  [3] Age,  sex,  HA,  A2M,  GGT,  bilirubin HCV F2 0.82/0.85
F4  0.89/0.94
Fibromètre  V  virus  [4] Age,  HA,  A2M,  PT,  platelets,  urea,  AST HCV,  HBV F2  0.89
F4  0.9
Fibromètre  A  alcohol  Age,  HA,  A2M,  PT  Alcohol  F2  0.96
Fibromètre  S  fatty  liver
disease
AST, ALT,  platelets,  ferritine,  blood
glucose,  weight,  age
Fatty  liver  disease  F2  0.96
A2M: alpha-2 macroglobulin; PT: prothrombin time; HA: hyaluronic acid; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human
immunodeﬁciency virus.
Table  2  The  principle  techniques  of  elastography.
The  different  elastography  techniques
Real  time  Dynamic  Impulse
Mechanical  Ultrasound
HI-RTE® (Hitachi)  MR  Touch® (GE)  Fibroscan® (Echosens)  ARFI® (Siemens)
Shear  Wave® elastography
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omeasured  in  m/s  using  ultrasound  imaging  in  the  tissue  being
studied  in  order  to  assess  its  stiffness.
Uni-dimensional  transient  elastography:
FibroScan®
Principle
The  FibroScan® (Echosens,  Paris,  France)  has  been  devel-
oped  around  10  years  ago  and  is  based  on  shear  wave,
which  is  generated  by  an  external  mechanical  impulse  and
whose  speed  is  measured  by  an  ultrasound  one-dimensional
probe.  The  one-dimensional  probe  (3.5  MHz)  is  mounted
along  the  axis  of  an  electro-dynamic  transducer  (vibrator).
The  FibroScan® estimates  liver  stiffness  by  measuring  the
velocity  of  elastic  shear  waves  in  the  liver  parenchyma  gen-
erated  by  the  mechanical  push.  The  propagation  velocity  is
directly  related  to  the  stiffness  of  the  medium,  deﬁned  by
the  Young  modulus.  Stiff  tissues  exhibit  higher  shear  wave
velocities  than  soft  tissues.  The  elasticity  is  expressed  in  kPa
(kilopascals)  and  is  measured  at  depth  ranging  from  25  to
65  mm  in  a  1  ×  4  cm  area:  the  assessed  liver  volume  is  there-
fore  two  hundred  times  greater  than  the  volume  examined
in  a  LB.  The  obtained  values  range  from  2.5  kPa  to  75  kPa.
Mean  liver  elasticity  in  ‘‘normal’’  subject  is  5.81  ±  1.54  and
5.23  ±  1.59  kPa  respectively  for  men  and  women  [7].  The
A
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•(Supersonic  Imaging)
easurement  is  painless  and  does  not  take  more  than  5  to
0  minutes  (Fig.  1).
atient  examination
atients  are  placed  in  the  supine  position,  with  the  right  arm
n  maximum  abduction  to  make  the  right  hypochondrium
ccessible  and  to  increase  intercostal  space.  Measurements
re  taken  in  the  right  lobe  of  the  liver  through  an  inter-
ostal  space  at  the  intersection  of  the  mid-axillary  line  and  a
ransverse  line  at  the  level  of  the  xiphoid  process.  The  inves-
igation  involves  ten  measurements.  The  result  produced  by
he  instrument  is  expressed  in  kPa  and  is  the  median  of  ten
easurements.  The  result  is  interpreted  as  a  METAVIR  equiv-
lent  score  (F0  to  F4)  by  the  expert  physician,  which  is  based
n  elasticity  cut-off  values  for  ﬁbrosis  stages  published  in  the
iterature  for  each  chronic  liver  disease.  The  apparatus  also
isplays  the  interquartile  range  (IQR)  and  success  rate  (num-
er  of  measurements  obtained  as  a  function  of  the  number
f  impulses  applied).dvantages
It is  a  rapid,  painless  technique;
the result  is  available  immediately;
it  can  be  carried  out  by  trained  paramedical  staff;
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•igure 1. Fibroscan®: a: Fibroscan® instrument; b: Fibroscan® pro
f result produced by the device.
intra-  and  inter-operator  reproducibility  is  excellent  with
an  intra-class  correlation  coefﬁcient  of  0.98  [8];
it  offers  good  diagnostic  accuracy  and  has  been  described
in  many  publications;
it  has  been  approved  by  the  HAS  to  ‘‘assess  untreated
chronic  hepatitis  C  without  comorbidities  in  adults  who
do  not  have  a  clear  diagnosis  of  cirrhosis’’  and  in
‘‘assessment  of  untreated  chronic  viral  hepatitis  C  with
HIV  co-infection  in  adults  without  a  clear  diagnosis  of
cirrhosis’’;
it  is  recommended  by  the  European  Association  for  the
Study  of  the  Liver  (EASL)  in  the  management  of  patients
with  chronic  viral  hepatitis  C  [9].imitations
Measurements  are  difﬁcult  when  intercostal  spaces  are
narrow,  the  chest  wall  is  thick,  in  case  of  obesity,  and  are
•
•
•: diagram summarising the principle of a measurement; d: example
impossible  in  the  presence  of  ascites.  The  average  fail-
ure  rate  is  3.1%  and  highly  depends  on  body  mass  index.
Measurements  are  unreliable  in  15.8%  of  cases  [10].  The
problem  of  overweight  is  being  resolved  with  the  develop-
ment  of  an  ‘‘XL  probe’’,  which  has  a reduced  failure  rate
in  obese  patients  (decreased  from  59%  for  the  M  probe  to
4.9%  for  the  XL  probe  for  patients  with  BMI  over  40  kg/m2)
[11];
the studied  hepatic  parenchyma  is  not  visualized  and
therefore  no  precise  knowledge  is  obtained  about  the
studied  segment.  Lack  of  visualization  of  the  studied  area
is  a  major  limitation  as  the  liver  can  be  heterogeneous,
with  areas  of  steatosis  and  more  or  less  ﬁbrotic;
the  left  side  of  the  liver  cannot  be  examined;
the  apparatus  is  expensive;
there  is  a  learning  curve  in  order  to  obtain  reliable  acqui-
sitions  without  ultrasound  guidance;
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• the  system  has  not  been  coupled  with  ‘‘standard  clini-
cal  ultrasound’’  and  cannot  provide  liver  morphological
examination.
Applications  and  diagnostic  performance
The  FibroScan® is  used  mostly  to  assess  liver  ﬁbrosis  in
chronic  liver  disease.
Diagnostic  performance  in  assessing  liver  ﬁbrosis.
In  recent  years,  many  prospective  studies  have  examined  the
diagnostic  performance  of  the  FibroScan® for  liver  ﬁbrosis
staging  in  chronic  liver  disease:  viral  hepatitis  C  [12], viral
hepatitis  B  [13],  HIV-HCV  co-infection  [14,15], alcoholic  liver
disease  [16]  and  NAFLD  [17].
In  most  of  the  world,  LB  is  still  considered  the  refer-
ence  test  to  determine  liver  ﬁbrosis  stages.  As  a  result,  all
diagnostic  technique  performance  studies  for  liver  ﬁbrosis
staging  have  compared  the  non-invasive  test  results  to  LB
histological  score  (METAVIR).  A  diagnostic  tool  is  deﬁned  as
being  perfect  if  the  area  under  the  ROC  curve  (AUROC)  is
100%,  excellent  if  the  AUROC  is  over  90%,  and  good  if  the
AUROC  is  over  80%  [18].  However,  the  diagnostic  perfor-
mance  of  LB  in  signiﬁcant  ﬁbrosis  is  only  moderate  (AUROC
approximately  0.8).  It  is  therefore  difﬁcult  to  precisely
determine  the  performance  of  non-invasive  markers  to  diag-
nose  signiﬁcant  ﬁbrosis,  as  the  reference  test  itself  is  less
than  perfect.
In  chronic  hepatitis  C  ﬁbrosis  staging  studies,  AUROC  of
TE  ranged  from  0.77  to  0.90  for  the  assessment  of  signiﬁ-
cant  ﬁbrosis  (F  ≥  2),  and  from  0.90  to  0.97  for  assessment  of
cirrhosis  respectively  [12,19—21].
Similar  results  have  been  found  in  other  diseases  such
as  chronic  hepatitis  B  and  HIV-HCV  co-infection.  It  appears,
however,  that  the  performance  of  the  FibroScan® is  slightly
poorer  in  the  diagnosis  of  alcoholic  cirrhosis  (AUROC  =  0.88)
than  for  viral  cirrhosis  (AUROC  =  0.94).
AUROC  values  in  chronic  viral  hepatitis  B  ranged  from
0.81  to  0.95  for  METAVIR  ﬁbrosis  scores  of  F  ≥  2  and  from
0.80  to  0.98  for  the  diagnosis  of  cirrhosis  [13,22—24].
AUROC  values  ranged  from  0.72  to  0.87  for  METAVIR  ﬁbro-
sis  scores  of  F  ≥  2  and  from  0.87  to  0.99  for  the  diagnosis  of
cirrhosis  [14,15]  in  HIV-HCV  co-infection.  Finally  and  more
recently,  studies  have  shown  the  utility  of  the  FibroScan® in
assessing  ﬁbrosis  in  non-viral  liver  disease  such  as  primary
biliary  cirrhosis,  primary  sclerosing  cholangitis,  Wilson’s  dis-
ease  and  even  in  some  patients  on  methotrexate  [25—28].
The  diagnostic  performance  of  the  FibroScan® has  been
examined  in  four  meta-analyses  [29—32].  Mean  AUROC  for
diagnosis  of  signiﬁcant  ﬁbrosis  and  cirrhosis  in  the  meta-
analysis  which  included  the  largest  number  of  studies  (n  =  50)
were  0.84  and  0.94,  respectively  [30].
Basis  of  interpretation:  what  cut-off  values  should
be used  for  liver  ﬁbrosis?  While  FibroScan® result  is  not
operator-dependent,  interpretation  of  the  result  is  part  of
the  overall  diagnosis  process  and  must  take  into  account  all
the  disease  clinical,  biological,  and  morphological  ﬁndings.
Interpretation  of  the  FibroScan® depends  on  the  reliability
of  the  measurement,  the  pathology  and  the  clinical  endpoint
and  goal  (sensitivity,  speciﬁcity,  positive  predictive  value
and  negative  predictive  value).
In  terms  of  the  result  quality,  the  measurement  is  deemed
to  be  ‘‘reliable’’  if  the  success  rate  is  over  60%,  the
interquartile  range  (IQR)  is  less  than  30%  of  the  median  value
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ven  below  21%  for  certain  authors  [8,33].  Elasticity  values
hould  also  be  interpreted  with  caution  in  thin  subjects,  as  a
ody  mass  index  of  under  19  k/m2 is  associated  with  greater
iscordance  between  ﬁbrosis  and  hepatic  elasticity.
In  terms  of  pathology,  it  is  important  to  distinguish  acute
epatitis  in  which  ‘‘elasticity’’  values  are  raised  and  corre-
ate  with  transaminase  levels,  from  chronic  liver  disease.  It
s  essential  in  chronic  liver  disease  to  interpret  liver  elastic-
ty  values  according  to  the  etiology.  Cut-off  values  offering
aximum  sensitivity,  speciﬁcity  and  positive  and  negative
redictive  values  vary  depending  on  etiologies  and  for  dif-
erent  studies.  In  chronic  viral  hepatitis  C,  cut-off  values
ange  from  6.2  to  8.7  kPa  to  predict  a  METAVIR  ﬁbrosis  score
f  F  ≥  2  and  from  9.6  to  14.8  kPa  for  the  diagnosis  of  cirrhosis
12,19—21]. In  chronic  viral  hepatitis  B,  the  cut-off  values
ange  from  6.3  to  7.9  kPa  to  predict  a  METAVIR  ﬁbrosis  score
f  F  ≥$2  and  from  9  to  13.8  kPa  for  the  diagnosis  of  cirrho-
is  [13,22—24]. In  HIV-HCV  co-infection,  the  cut-off  values
ange  from  4.5  to  9.3  kPa  for  a  METAVIR  ﬁbrosis  score  of  F  ≥  2
nd  from  11.8  to  14  kPa  for  the  diagnosis  of  cirrhosis  [14,15].
Table  3  summarizes  the  diagnostic  performance  and  opti-
al  cut-off  values  to  diagnose  ﬁbrosis  stages  F  ≥  2,  F  ≥  3  and
 =  4  [8,12—15,19—21,23,24,26,29,30,34—38].
Optimal  cut-off  values  in  Friedrich’s  meta-analysis  were
.6  and  13.01  kPa  [30],  for  the  diagnosis  of  signiﬁcant  ﬁbrosis
≥  F2)  and  cirrhosis  (=  F4)  respectively.  Most  of  the  stud-
es  included  in  this  meta-analysis  were  based  on  western
opulations  with  isolated  HCV  infection  and  consequently,
t  would  be  unwise  to  apply  these  cut-off  values  from  pre-
ious  meta-analysis  to  patients  with  diverse  chronic  liver
isease  etiologies.  Finally,  some  authors  do  not  consider  it
easonable  to  interpret  a  FibroScan® value  against  a  cut-
ff,  but  rather  according  to  a  likely  ‘‘range’’  of  correlation
etween  liver  ﬁbrosis  and  the  FibroScan® value  in  which
hese  ‘‘ranges’’  vary  depending  on  etiology  [39].
coustic  Radiation  Force  Impulse  Imaging  mode
lastography
rinciple
coustic  Radiation  Force  Impulse  (ARFI)  imaging  is  a  new
ethod  for  quantifying  mechanical  properties  of  tissue,
ithout  manual  compression,  by  measuring  the  shear  wave
elocity  induced  by  acoiustic  radiation  and  propagating  in
he  tissue.  This  technique  has  been  developed  by  Siemens
nd  is  available  on  Acuson  S2000  and  S3000  ultrasound  diag-
ostic  imaging  devices  (Issaquah,  WA,  USA),  and  on  the
U22  diagnostic  imaging  device  developed  by  Philips  (Both-
ll,  WA,  USA).  This  quantitative  technique  provides  a  single
ni-dimensional  measurement  of  tissue  elasticity  like  the
ibroScan®,  although  the  measurement  area  can  be  pos-
tioned  on  a  two-dimensional  Bmode  image.  The  region  is
 1  ×  0.5  cm  rectangular,  which  can  be  freely  moved  in  the
wo-dimensional  Bmode  image  to  a  maximum  depth  of  8  cm
rom  the  skin  plane.  The  measurement  is  expressed  in  m/s,
xpressing  shear  wave  speed,  travelling  perpendicular  to  the
hear  wave  source.  The  technique  has  been  implemented
n  the  ultrasound  probe  designed  for  abdominal  imaging
Fig.  2).atient  examination
lastrography  measurements  can  be  performed  just  after
orphological  and  Doppler  vascularization  examination  of
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Table  3  Performance  of  the  Fibroscan® and  cut-off  values  to  diagnose  signiﬁcant  ﬁbrosis  (F  ≥  F2),  severe  ﬁbrosis  (F  ≥  F3)
and  cirrhosis  (F  =  F4).
Authors  Patients(n)  Diseases  AUROC  FS  Cut-off  values  FS  (kPa)
≥  F2 ≥  F3 =  F4 ≥  F2  ≥  F3  =  F4
Ziol  et  al.  [12]  251  HCV  0.79  0.91  0.97  8.8  9.6  14.6
Castera  et  al.  [19] 183  HCV  0.83  0.9  0.95  7.1  9.5  12.5
Rigamonti  et  al.  [34] 90  HCV  0.93  0.97  —  7.8  12  —
Carrion  et  al.  [35] 124  HCV  0.9 0.93  0.98  8.5  —  12.5
Arena  et  al.  [20] 150  HCV  0.91 — 0.98  7.8 —  14.8
Nitta  et  al.  [36]  165  HCV  0.88  —  0.9  7.1  9.6  11.6
Sirli  et  al.  [37]  150  HCV  0.77  —  0.97  6.8  —  13.3
Kim  et  al.  [21]  91  HCV  0.9  —  0.97  6.2  —  11
Marsellin  et  al.  [13]  173  HBV  0.81  0.93  0.93  7.2  —  11
Zhu  et  al.  [23]  175  HBV  0.95  —  0.98  7.9  —  13.8
Ogawa  et  al.  [24]  44  HBV  0.86  —  0.89  6.3  —  12
Corpechot  et  al.  [26]  95  Cholestatic  diseases  0.92  0.95  0.96  7.3  9.8  17.3
Fraquelli  et  al.  [8]  200  All  liver  diseases  0.84  0.87  0.90  7.9  10.3  11.93
Gomez-Dominguez  [38]  103  All  liver  diseases  0.74  0.72  0.94  5  11  16
De  ledinghen  et  al.  [14]  72  HIV-HCV  0.72  0.91  0.97  4.5  —  11.8
Vergara  et  al.  [15]  169  HIV-HCV  0.88  —  0.95  7.2  —  14.6
Friedrich-Rust  et  al.  [30] a All  liver  diseases  0.84  0.89  0.94  7.6  —  13.01
Talwalkar  et  al.  [29] a All  liver  diseases  0.87  —  0.96
AUROC: area under the ROC curve; FS: FibroScan®; HCV: hepatitis C virus; HBV: hepatitis B virus; HIV: human immunodeﬁciency virus.
a Meta-analysis.
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•he  liver.  Patients  are  placed  in  the  supine  position,  with
he  right  arm  in  maximum  abduction  to  make  the  right
ypochondrium  accessible  and  to  increase  intercostal  space
to  improve  the  acoustic  window).  The  probe  is  placed  par-
llel  to  the  intercostal  space  within  the  space  with  sufﬁcient
el  in  order  to  minimize  rib  shadowing.  The  region  of  inter-
st  is  positioned  within  the  liver  parenchyma  under  visual
ontrol  in  two-dimensional  B-mode,  distant  from  vessels  and
 cm  beneath  the  Glisson’s  capsule  [40].  When  ARFI  is  acti-
ated,  the  measurement  (m/s)  is  displayed  on  the  screen
fter  a  few  seconds.  The  manufacturer  has  not  given  any
ecommendations/guidelines  about  the  practical  process  for
n  examination.  In  practice,  ten  measurements  are  taken  in
he  right  lobe  of  the  liver,  in  the  intercostal  space  with  the
atient  holding  his/her  breath  gently.  Measurement  should
e  avoided  after  deep  inspiration,  which  increases  ARFI  val-
es  signiﬁcantly  by  an  average  of  13%  [41].  The  median,
ean  and  standard  deviation  of  the  ten  measurements  are
alculated  (for  the  Philips  device  only).
dvantages
It is  an  easy,  rapid,  painless  technique;
results  are  available  after  a  few  seconds;
intra-operator  (intra-class  correlation  coefﬁcient
ICC  = 0.9)  and  inter-operator  (ICC  =  0.81)  producer
ability  is  good  [42];
visual  control  of  measurement  location  unlike  FibroScan®,
with  the  ability  to:
◦ avoid  vascular  structures  when  taking  measurements,
◦ study  regions  of  interest  (area  of  steatosis,  liver  with
tumor),
A
T
ﬁ◦ correlate  elasticity  to  the  tissue  architecture  seen
(necrosis,  steatosis),
◦ study  the  right  and  left  lobes  of  the  liver;
the  ability  to  select  the  measurement  depth,  unlike  the
FibroScan®;
good diagnostic  performance:  although  still  undergoing
assessment  this  technique  has  already  appeared  in  many
publications;
ARFI  is  incorporated  onto  a conventional  ultrasound  diag-
nostic  imaging  device,  which  allows  the  combination,  in
one  exam,  of  quantitative  elastography  after  a  complete
morphological  ultrasound  examination  of  the  liver  (to
investigate  for  signs  of  cirrhosis,  portal  hypertension  and
to  identify  focal  lesions).
imitations
The  elasticity  measurement  is  not  given  in  real  time;
the  elasticity  measurement  cannot  be  performed  retro-
spectively;
only  one  acquisition  can  be  taken  at  a  time;
the  measurement  region  is  a  small,  predetermined  area,
the  size  of  which  cannot  be  changed;
only  the  mean  shear  wave  speed  of  the  measurement
region  is  calculated,  with  no  information  about  the
standard  deviation;
there  are  no  quality  criteria  to  accept  or  exclude  the
measurement;
the  technique  has  not  been  validated  as  extensively  as
transient  elastography  (FibroScan®).pplication  and  diagnostic  performance
he  main  indications  of  ARFI  in  the  liver  are  assessment  of
brosis  and  characterization  of  hepatic  tumors.
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the principle of a measurement with the ‘‘Virtual Touch Tissue Quan
Diagnostic  performance  in  the  assessment  of  liver
ﬁbrosis.  Although  it  has  been  less  investigated  than
transient  elastography,  diagnostic  performance  of  ARFI  is
showing  promises.  AUROC  values  in  a  study  conducted  by
Sporea  et  al.  on  274  patients  with  isolated  HCV  infection
were  calculated  retrospectively  to  be  0.893,  0.908  and
0.937  to  predict  ﬁbrosis  stages  F  ≥  F2,  F  ≥  F3  and  F  =  F4  [43]
respectively.  AUROC  values  in  a  meta-analysis  performed  by
Friedrich-Rust,  which  included  518  patients  with  combined
chronic  liver  diseases,  were  calculated  retrospectively  to  be
0.87  to  diagnose  signiﬁcant  ﬁbrosis  (F  ≥  2),  0.91  to  diagnose
severe  ﬁbrosis  (F  ≥  3),  and  0.93  to  diagnose  cirrhosis  [44].
Overall,  ARFI  can  be  considered  to  be  an  adequate  diagnos-
tic  technique  for  the  assessment  of  ﬁbrosis,  particularly  in
chronic  viral  hepatitis  C  (where  the  AUROC  is  > 0.8  regardless
of  the  stage  of  ﬁbrosis).  A  comparative  meta-analysis  of  the
diagnostic  performance  of  ARFI  and  the  FibroScan®,  how-
ever,  showed  that  results  varied  depending  on  the  study.  The
diagnostic  performance  results  for  ARFI  in  the  different  stud-
ies  are  summarized  in  Table  4  [40,45—54].  The  diagnostic
®performance  of  ARFI  and  FibroScan was  identical  to  pre-
dict  severe  ﬁbrosis,  regardless  of  the  study  author  [40,45,46]
whilst  for  some  authors,  the  diagnostic  performance  of  the
FibroScan® appeared  to  be  better  than  the  ARFI  [40,46]  to
a
v
T
we ARFI® software has been implemented; b: diagram summarizing
tion Imaging’’ system; c: example of result produced by the device.
redict  F  ≥  1 or  F  ≥  2  and  was  the  same  according  to  other
uthors  [45].  More  recently,  Rizzo  et  al.  have  shown  ARFI  to
erform  better  than  FibroScan® regardless  of  ﬁbrosis  stage
52]. The  comparison  of  ARFI  with  FibroScan® in  312  patients
rom  four  different  studies  in  the  meta-analysis  by  Friedrich-
ust  showed  results  to  be  similar  for  the  two  techniques  to
redict  severe  ﬁbrosis  and  slightly  superior  performance  for
he  FibroScan® to  diagnose  signiﬁcant  ﬁbrosis  and  cirrhosis
44]. The  number  of  patients  involved,  however,  was  not
arge  enough  to  draw  deﬁnitive  conclusions.
Bases  for  interpretation  —  what  cut-off  values
hould be  used  for  liver  ﬁbrosis?  The  interpretation  of
n  ARFI  examination  depends  amongst  other  things  on  the
eliability  of  the  measurements  and  the  etiology.  Although
he  manufacturer  has  not  produced  any  recommendations
bout  the  reliability  of  the  measurements,  some  authors
ecommended  that  the  same  criteria  are  used  as  for  the
ibroScan® (success  rate  ≥  60%  and  IQR  <  30%)  [55].
The  cut-off  values  used  to  deﬁne  the  different  stages
f  ﬁbrosis  as  METAVIR  equivalents  vary  with  etiologies
nd  publication.  The  diagnostic  performance  and  cut-off
alues  for  the  different  stages  of  ﬁbrosis  are  shown  in
able  4.  In  Friedrich’s  meta-analysis  these  cut-off  values
ere  1.34  m/s,  1.55  m/s  and  1.80  m/s  to  predict  ﬁbrosis
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Table  4  Performance  of  the  Fibroscan® and  Acoustic  Radiation  Force  Impulse  Imaging  (ARFI)  and  optimal  cut-off  values  for  ARFI  to  diagnose  signiﬁcant  ﬁbrosis
(F  ≥  F2),  severe  ﬁbrosis  (F  ≥  F3)  and  cirrhosis  (F  =  F4).
Authors  Patients(n)  Diseases  AUROC  Fibroscan® AUROC  ARFI  ARFI  cut-off  values  (m/s)
≥  F2  ≥  F3  =  F4  ≥  F2  ≥  F3  =  F4  ≥  F2  ≥  F3  =  F4
Friedrich-Rust  et  al.  [45]  70  HCV  0.84  0.9  0.91  0.82  0.91  0.91  1.35  1.55  1.77
Lupsor  et  al.  [46]  112  HCV  0.941a 0.926  0.945  0.851a 0.869  0.911  1.34  1.61  2
Takahashi  et  al.  [47]  55  Chronic  liver  disease  —  —  —  0.94  0.94  0.96  1.34  1.44  1.8
Fierbinteanu-Braticevici  et  al.  [48]  74  HCV  —  —  —  0.972  0.993  0.99  1.21  1.54  1.94
Goertz  et  al.  [49]  57  HCV—HBV  —  —  —  0.85  0.92  0.87  —  —  —
Yoneda  et  al.  [50]  54  NAFLD  —  0.99  0.998  —  0.973  0.976  —  1.77  1.9
Sporea  et  al.  [40]  114  Chronic  liver  disease  0.908a —  0.99  0.767a —  0.95  —  1.78
Sporea  et  al.  [53]  223  Chronic  liver  disease  0.953a —  0.985  0.89a —  0.931  1.27  —  1.7
Rizzo  et  al.  [52]  139  HCV  0.78a 0.83a 0.8a 0.86a 0.94a 0.89a 1.3  1.7  2
Sporea  et  al.  [51]  197  HCV  0.87  —  0.97  0.84  —  0.91  1.2  —  1.8
Friedrich-Rust  et  al.  [44]  518  (ARFI)  Chronic  liver  disease  —  —  —  0.87  0.91  0.93  1.34  1.55  1.8
Sporea  et  al.  [54]  911  (ARFI)  HCV  —  —  —  0.792  0.829  0.842  1.33  1.43  1.55
400  (FS)  0.818  0.866  0.932  0.813  0.862  0.885  1.36  1.47  1.69
FS: FibroScan®; HCV: hepatitis C virus; HBV: hepatitis B virus; NAFLD: non-alcoholic fatty liver disease; AUROC: area under the ROC curve.
a Statistically different signiﬁcance between the diagnostic performance of the two techniques.
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stages  F  ≥  2,  F  ≥  3  and  F  =  4,  in  combined  chronic  liver  dis-
eases,  [44].  The  cut-off  values  in  Sporea’s  multicentre  study
were  1.33  m/s  (AUROC  =  0.792),  1.43  m/s  (AUROC  =  0.829)
and  1.55  m/s  (AUROC  =  0.842)  to  predict  ﬁbrosis  of  F  ≥  2,
F  ≥  3 and  F  =  4  respectively  in  patients  with  chronic  hepatitis
C  [54].
Shear  Wave  Elastography® (SWE)
Principle
Shear  wave  elatography  (SWE)  was  introduced  in  2005  on  the
diagnostic  Imaging  device,  called  AixplorerTM (SuperSonic
Imagine,  Aix-en-Provence,  France).  It  relies  on  the  measure-
ment  of  the  shear  wave  propagation  speed  in  soft  tissue;  Like
ARFI,  it  does  not  require  an  external  vibrator  to  generate
the  shear  wave.  It  is  based  on  the  generation  of  a  radiation
force  in  the  tissue  to  create  the  shear  wave.  The  ultrasound
probe  of  the  device  produces  a  very  localized  radiation
force  deep  in  the  tissue  of  interest.  This  acoustic  radiation
force/push  induces  a  shear  wave,  which  then  propagates
from  this  focal  point.  Several  focal  points  are  then  generated
almost  simultaneously,  in  a  line  perpendicular  to  the  sur-
face  of  the  patient’s  skin.  This  creates  a  conical  shear  wave
front,  which  sweeps  the  image  plane,  on  both  sides  of  the
focal  point.  The  progression  of  the  shear  wave  is  captured
by  the  very  rapid  acquisition  of  ultrasound  images  (up  to
20,000  images  per  second),  called  UltraFastTM Imaging.  The
acquisition  takes  only  a  few  milliseconds,  thus  the  patient
or  operator  movement  does  not  impact  the  result.  A  high-
speed  acquisition  is  necessary  to  capture  the  shear  wave  as  it
moves  at  a  speed  in  the  order  of  1  to  10  m/s.  A  comparison  of
two  consecutive  ultrasound  images  allows  the  measurement
of  displacements  induced  by  the  shear  wave  and  creates  a
‘‘movie’’  showing  the  propagation  of  the  shear  wave  whose
local  speed  is  intrinsically  linked  to  elasticity.  The  propa-
gation  speed  of  the  shear  wave  is  then  estimated  from  the
movie  that  is  created  and  a  two-dimensional  color  map  is
displayed,  for  which  each  color  codes  either  the  shear  wave
speed  in  meters  per  second  (m/s),  or  the  elasticity  of  the
medium  in  kilopascals  (kPa).  This  color  map  is  accompanied
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Figure 3. Shear Wave elastography: a: ultrasound diagnostic imaging
implemented; b: example of result provided by the instrument: color ma523
y  an  anatomic  reference  gray  scale  (or  B-mode)  image.  This
uantitative  imaging  technique  is  a  real-time  imaging  mode.
uantitative  measurements  can  be  performed  in  the  color
indow  by  positioning  one  or  more  ROI  (regions  of  interest)
alled  Q-Box.  The  Q-Boxes  are  variable  in  size  (from  3  mm2
o  700  mm2).  Measurements  can  be  performed  retrospec-
ively  from  the  saved  image  or  cineloop.  The  measurements
rovided  by  Q-Box  are  the  mean,  standard  deviation,  and
inimum  and  maximum  elastography  values.  Results  are
iven  in  m/s  or  kPa  (Figs.  3  and  4).
rocess  of  the  investigation
s  for  ARFI,  SWE  acquisition  can  be  performed  just  after  a
omplete  morphological  and  Doppler  vascularization  exami-
ation  of  the  liver.  Patients  are  placed  in  the  supine  position,
ith  the  right  arm  in  maximum  abduction  to  make  the
ight  hypochondrium  accessible  and  to  increase  intercostal
pace  (to  improve  the  acoustic  window).  The  probe  is  placed
arallel  to  the  intercostal  space  within  the  space  with  suf-
cient  gel  in  order  to  minimize  rib  shadowing.  To  insure
eliable  SWE  acquisition  and  contrary  to  what  has  been  rec-
mmended  as  a rule  for  most  of  the  organs,  a  pressure
ust  be  applied  to  the  probe  when  scanning  the  liver.  It
llows  a  better  acoustic  coupling  by  opening  the  rib  space
nd  decreasing  tissue  thickness  between  the  probe  and  the
ibs  (The  ribs  will  absorb  the  pressure  and  the  elasticity  of
he  liver  will  not  be  impacted).  When  SWE  is  activated,  a
eal  time  two-dimensional  box  appears  overlaid  on  the  B-
ode  with  an  elastography  map.  The  window  is  positioned
ithin  the  liver  parenchyma,  avoiding  artifact  from  vessels
nd  2  cm  beneath  the  Glisson’s  capsule.  It  is  essential  that
he  operator  waits  for  2  to  3  seconds  in  order  for  the  sig-
al  to  stabilize  before  freezing.  The  2D  acquisition  window
ffers  a qualitative  approach  to  the  stiffness  of  the  tissue
sing  color  mapping.  Measurements  are  taken  with  patients
olding  their  breath  gently,  without  deep  inspiration.  The
anufacturer  recommends  that  three  acquisitions  be  taken
n  the  same  area  of  liver  parenchyma  and  that  the  average  of
he  values  provided  by  the  Q-Box  be  calculated  (Fig.  3).  The
 device onto which Shear Wave elastography software has been
pping and Qbox.
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emporal  stability  is  also  a  good  criteria  to  insure  reliable
WE  acqusitions.
dvantages
It is  an  easy,  painless,  rapid  technique;
good  intra-operator  reproducibility  with  an  intra-class
correlation  coefﬁcient  of  0.95  when  measurements  are
taken  the  same  day  and  0.84  when  they  are  taken  at
different  days  by  the  same  operator  [56];
good  inter-operator  reproducibility  (ICC  =  0.88)  [56];
the  result  is  immediately  available;
SWE  is  incorporated  onto  a  conventional  ultrasound  diag-
nostic  imaging  device,  which  allows  the  combination,  in
one  exam,  of  quantitative  elastography  assessment  of
the  liver  ﬁbrosis  and/or  tumor  after  the  morphological
ultrasound  examination  of  the  liver  (to  investigate  for
signs  of  cirrhosis,  portal  hypertension  and  to  identify  focal
lesions);
quantitative  assessment  of  soft  tissue  elasticities  in  kPa
or  in  m/s;
real  time  two-dimensional  map  of  tissue  elasticities;
visual  control  of  measurement  location  unlike  FibroScan®,
with  the  ability  to:
◦ avoid  vascular  structures  when  performing  acquisition,
◦ study  regions  of  interest  (area  of  steatosis,  liver  with
tumor)  and  visualize  the  spatial  distribution  of  ﬁbrosis,
◦ correlate  elasticity  to  the  tissue  architecture  seen
(necrosis,  steatosis),
◦ study  the  right  and  left  lobes  of  the  liver;
the  ability  to  select  the  measurement  depth,  and  an  area
free  of  SWE  artifact  (due  to  vessels,  Glisson’s  capsule,  or
other  lesions);
the  ability  to  perform  several  measurements  retrospec-
tively  on  saved  images  on  the  device;
the  ability  to  choose  the  size  of  the  ‘‘Q-Box’’;
results  expressed  and  displayed  in  kPa  or  m/s.
imitations
t  is  a  recent  technique,  which  needs  to  be  evaluated,
lthough  initial  results  are  promising.
pplications  and  diagnostic  performance
s  for  ARFI,  the  main  indications  are  assessment  of  liver
brosis  and  examination  of  liver  tumors.
Diagnostic  performance  in  the  assessment  of  liver
brosis.  As  this  is  a  more  recent  technique,  there  are  few
ublished  studies  at  present.  The  calculated  AUROC  values
n  the  study  performed  by  Ferraioli  et  al.  were  0.92  and
L
•
•color mapping.
.84  for  Shear  Wave  elastography  and  FibroScan® respec-
ively  to  differentiate  F0-F1  compared  to  F2-F4,  0.98  and
.96  to  distinguish  F0-F2  compared  to  F3-F4,  and  0.98  and
.96  to  distinguish  F0-F3  compared  to  F4.  According  to  this
tudy,  Shear  Wave  elastography  performs  better  than  the
ibroScan® to  diagnose  signiﬁcant  ﬁbrosis  (≥  F2)  [57].  Other
tudies,  however,  are  needed  to  draw  deﬁnitive  conclusions.
Bases  for  interpretation  —  what  cut-off  values
hould be  used  for  liver  ﬁbrosis?.  The  optimal  cut-off
alues  for  SWE  are  for  the  different  ﬁbrosis  stages  7.1  kPa
or  F  ≥  2;  8.7  kPa  for  F ≥  3  and  10.4  kPa  for  F  =  4  respectively
57].
tatic elastography
tatic  elastography
rinciple
he  initial  systems  were  developed  by  Hitachi  (EUB-8500,
UB  900).  The  operator  manually  applies  gentle  pressure
ith  the  ultrasound  probe  in  order  to  induce  in  the  under-
ying  tissues  a  deformation.  In  this  situation,  only  the
eformed  tissue  subject  to  the  manual  compression  is  mea-
ured,  rather  than  a  direct  measurement  of  elasticity.  The
eformation  is  considered  to  be  inversely  proportional  to
lasticity.  A  color  map  of  tissue  elasticity  is  obtained:  this  is
 qualitative  approach  (Fig.  5).  In  more  recent  systems,  the
eformation  of  the  liver  parenchyma  as  a  result  of  vascu-
ar  beating  or  respiration  alone  has  also  been  used  (Philips,
itachi.  .  .).
dvantages
It is  a  fast,  painless,  reproducible  technique;
ascites  is  not  a  limiting  factor;
visual  control  of  measurements;
the  results  are  immediately  available;
real  time  elastography  is  incorporated  onto  a  conven-
tional  ultrasound  diagnostic  imaging  device,  which  allows
the  combination,  in  one  exam,  of  elastography  assessment
of  the  liver  ﬁbrosis  and/or  tumor  after  the  morphologi-
cal  ultrasound  examination  of  the  liver  (to  investigate  for
signs  of  cirrhosis,  portal  hypertension  and  to  identify  focal
lesions).imitations
It is  a  non-quantitative  technique;
it  is  operator-dependent  (for  manual  compression  sys-
tems);
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•Figure 5. Standard elastography: Hi-RTE: a: ultrasound; b: exam
• lack  of  information  in  the  literature;
• lack  of  standardization  for  the  technique.
Process  of  an  investigation
Patients  are  positioned  on  their  back  with  their  right  arm
raised  behind  their  head.  The  depth  of  elastography  mea-
surement  ranges  from  20  to  50  mm  with  a  region  of  interest
of  350  to  500  mm2.  The  results  are  deemed  to  be  reliable  if
the  manual  pressure  exercised  is  3—4  on  an  arbitrary  scale
ranging  from  0  to  6  (Fig.  5).  Ten  acquisitions  are  taken  from
the  right  lobe  of  the  liver  in  the  intercostal  space  with  free
respiration.  The  ‘‘relative  elasticity’’  of  the  tissue  is  deter-
mined  and  represented  on  a  color  map  on  conventional  B
mode  imaging.  Hard  tissues  appear  in  blue  and  soft  tis-
sues  in  red.  Different  elasticity  scores  have  been  described
[58—60].
Application  and  diagnostic  performance
The  main  applications  are  measurement  of  liver  ﬁbrosis  and
an  investigation  of  liver  tumours.
Diagnostic  performance  for  the  assessment  of  liver
ﬁbrosis  and  basis  for  interpretation.  Different  elastic-
ity  scores  have  been  published  up  to  now  in  the  literature:
• the  ‘‘German  elasticity’’  score  (between  65  and  122),
with  calculated  AUROC  values  of  0.75  for  a  diagnosis  of
signiﬁcant  ﬁbrosis  (F  ≥  2),  0.73  for  a  diagnosis  of  severe
ﬁbrosis  (F  ≥  3),  and  0.69  for  a  diagnosis  of  cirrhosis  [58];
• the  ‘‘Japanese  elasticity’’  score  (between  0  (blue)  and
255  (red))  [59];
• the  liver  ﬁbrosis  index,  with  AUROC  values  of  0.784  to
differentiate  F0-F1  from  F3-F4,  and  0.803  to  differentiate
F0-F3  from  F4  [60].
Whilst  the  initial  publications  showed  that  the  RTE  tech-
nique  did  not  perform  better  than  the  other  non-invasive
methods,  the  technology  has  been  improved  since  then  and
more  recent  studies  have  shown  more  encouraging  results
[61,62].
Colombo  et  al.  compared  the  diagnostic  performance  of
three  ultrasound  elastography  techniques:  ARFI,  FibroScan®
and  a  new  real-time  elastography  technique  (RTE).  Theref measurement [58].
as  no  signiﬁcant  difference  between  the  three  techniques
n  the  diagnosis  of  cirrhosis  (calculated  AUROC  values  of
.922,  0.934  and  0.852  for  the  FibroScan®, ARFI  and  RTE
espectively).  The  FibroScan®, however,  performed  as  well
s  ARFI  but  signiﬁcantly  better  than  RTE  to  predict  signiﬁ-
ant  ﬁbrosis  (calculated  AUROC  values  of  0.897,  0.815  and
.751  respectively)  [63]. Finally,  although  the  latest  results
btained  with  the  new  RTE  technique  appears  to  open  new
uture  prospects  for  this  type  of  liver  elastography,  this
pproach  is  still  too  limited  in  terms  of  diagnostic  perfor-
ance  to  be  recommended  in  clinical  practice.
pplication of US elastography techniques
part  from  ﬁbrosis  assessment  indication,  the  applications
f  US  elastography  to  the  liver  are  prediction  of  cirrhosis-
elated  complications,  characterization  of  focal  lesions,  and
onitoring  interventional  radiology  treatments.
ssessment of ﬁbrosis
hich  method(s)  should  be  chosen  to  assess  liver
brosis?
AS  recommendations  for  assessment  of  liver  ﬁbrosis
n chronic  liver  disease
To  diagnose  cirrhosis  [64].
In isolated  chronic  hepatitis  C  without  co-morbidities
and  not  previously  treated:  a  non-invasive  test  is  rec-
ommended  such  as  shear  wave  based  elastography
(Fibroscan®,  ARFI  or  SWE)  or  blood  serum  marker  test
(Fibrotest®,  FibroMètre® or  Hépascore®),  as  ﬁrst  inten-
tion  test.  At  the  second  intention  test,  a  non-invasive  test
and/or  needle  liver  biopsy  are  recommended;
in  HIV-HCV  co-infection:  a  non-invasive  test  such  as  shear
®wave  based  elastography  (Fibroscan ,  ARFI  or  SWE)  or
blood  serum  marker  test  (Fibrotest®, FibroMètre® or
Hépascore®),  is  recommended  as  a  ﬁrst  intention  test,
with  LB  as  second  intention  test;
5 N.  Frulio,  H.  Trillaud
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a needle  liver  biopsy  must  be  performed  for  all  other
etiologies  and  treatment  cases.
To  diagnose  ﬁbrosis,  regardless  of  stage  [65].  In
hronic  hepatitis  C  infection  in  an  untreated  adult  and
n  the  absence  of  a  concomitant  cause  or  co-morbidity,
epatic  ﬁbrosis  may  be  assessed  ﬁrst  line  from  a  non-invasive
est  (impulse  elastography  or  Fibrotest®).  The  limitations
f  the  use  of  these  two  techniques  must  be  understood.
heir  results  must  be  interpreted  taking  account  the  clin-
cal  context  and  by  a  trained  clinician.  If  the  result  of  the
on-invasive  test  is  not  consistent  with  the  clinical  situation,
r  if  the  test  fails  technically  (impulse  elastography)  or  if  an
bnormality  is  present  hindering  interpretation  (Fibrotest®),
nother  diagnostic  method  is  required.  Use  of  the  second
alidated  non-invasive  method  would  appear  to  be  logical  if
t  can  be  performed  and  can  be  interpreted.  Another  pos-
ible  option  is  a  LB  either  initially  or  if  the  results  of  two
on-invasive  tests  are  inconsistent.
In  other  situations,  such  as  chronic  hepatitis  C  in  a
reated  patient,  or  if  a  concomitant  cause  or  co-morbidity
s  present,  and  in  chronic  liver  disease  due  to  other  causes
particularly  alcohol  or  HBV)  and  in  childhood  liver  disease,
he  only  currently  validated  assessment  method  for  liver
brosis  remains  LB.
Similarly,  to  monitor  patients  suffering  from  chronic  liver
isease  or  to  assess  the  results  of  antiviral  treatments:
performing  the  shear  wave  based  elastography  in  com-
bination  with  blood  serum  marker  test  has  not  been
validated  today  to  assess  progression  of  liver  lesions
because  of  insufﬁcient  data;
ﬁnally,  the  combination  of  shear  wave  based  elastogra-
phy  in  combination  with  blood  serum  marker  test  has
not  yet  been  validated  to  assess  the  results  of  antiviral
treatments.
n  practice
t  appears  obvious  that  in  the  near  future  there  will  not  be  a
ingle  method  used  in  preference  but  a  combination  of  sev-
ral  non-invasive  methods,  leading  to  patient  management
lgorithms.  New  approaches  involving  combining  the  non-
nvasive  methods  have  recently  been  established  in  order
o  improve  diagnostic  performance.  The  Castera  algorithm,
hich  combines  the  FibroScan® and  Fibrotest®,  can  be  used
o  avoid  liver  biopsy  in  approximately  75%  of  cases  [19,66]
Fig.  6).  The  algorithm  by  Boursier  et  al.,  which  combines
he  Fibromètre® and  FibroScan®,  can  avoid  biopsy  in  80%  of
ases  [67].  Sporea  et  al.  have  also  shown  that  the  combina-
ion  of  FibroScan® and  ARFI  can  increase  the  speciﬁcity  for
he  diagnosis  of  signiﬁcant  of  ﬁbrosis  with  a  PPV  96.8%  when
he  two  techniques  are  combined  to  predict  F  ≥  2,  and  an
PV  of  94.4%  to  predict  F4  [51].
eimbursement  of  non-invasive  methods  by  the
rench National  Health  Insurance  system
ests  for  measurement  of  liver  elasticity  using  impulse  elas-
ography  and  serum  marker  tests  for  the  assessment  of
iver  ﬁbrosis  (Fibrotest®,  Fibromètre® or  Hépascore®)  are
eimbursed  by  the  French  National  Health  Insurance  funds
ince  May  2011,  only  within  the  indications  recommended
y  the  HAS  and  to  a  limit  of  once  a  year  except  if  risk
actors  of  rapid  progression  to  cirrhosis  are  present.  The
s
F
[
figure 6. Algorithm from Castera et al. [19].
eimbursement  for  the  shear  wave  based  elastography  pro-
edure  is  31.29  euros  in  France.
aution  in  the  interpretation  of  non-invasive
ethods
hile  elastography  techniques  have  good  diagnosis  perfor-
ance,  the  interpretation  of  their  results  is  part  of  the
verall  diagnosis  process  and  must  take  into  account  all
he  disease  clinical,  biological,  and  morphological  ﬁnd-
ngs.  Interpretation  of  the  elastography  results  depends  on
he  reliability  of  the  measurement,  the  pathology  and  the
linical  endpoint  and  goal  (sensitivity,  speciﬁcity,  positive
redictive  value  and  negative  predictive  value).  Cut-off
alues  have  been  validated  for  each  elastography  tech-
ique  in  order  to  determine  the  different  stages  of  ﬁbrosis
s  METAVIR  equivalents.  Stiffness  is  not  ‘‘synonymous  to
brosis’’  and  other  confounding  factors  may  inﬂuence
lastography  results:  extra  hepatic  cholestasis  [68],  liver
ongestion  [69], acute  hepatitis  and  cytolytic  changes,  and
ecrotic  and  inﬂammatory  lesions  [70,71].  Results  must  be
nterpreted  by  a  doctor  who  is  an  expert  in  ‘‘hepatic  elas-
icity’’.
rediction of cirrhosis-linked complications
rediction  of  development  of  oesophageal  varices
OV)
arious  publications  have  assessed  the  utility  of  the
ibroScan® and  ARFI  in  predicting  development  of  por-
al  hypertension  and  oesophageal  varices  [72—76].  Several
tudies  have  demonstrated  a  signiﬁcant  correlation  between
ibroScan® values  and  the  presence  of  oesophageal  varices
72—74].  Although  results  are  encouraging,  diagnostic  per-
ormance  varies  according  to  the  studies  (AUROC  values
ﬁ
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range  from  0.76  to  0.85  for  the  FibroScan® and  from  0.58
to  0.9  for  ARFI)  and  considerable  variations  exist  in  the  cut-
off  values.  For  these  reasons,  impulse  elastography  cannot
at  present  be  used  to  select  patients  who  need  to  undergo
endoscopy.  Other  studies  are  therefore  necessary,  proba-
bly  in  the  future  using  a  combination  of  several  factors  to
increase  diagnostic  accuracy.
Prediction  of  development  of  hepatocellular
carcinoma
Several  studies  have  shown  that  the  risk  of  developing  HCC
increases  in  parallel  with  hepatic  elasticity  values:  patients
with  higher  FibroScan® values  are  at  greater  risk  of  devel-
oping  HCC.  In  addition,  elasticity  values  are  considered  to
be  an  independent  risk  factor  for  developing  HCC  [77]. Ver-
mehren  et  al.  compared  the  diagnostic  performance  of  ARFI
in  the  liver  and  spleen  to  that  of  the  FibroScan® and  the
Fibrotest® in  predicting  the  development  of  HCC  in  patients
with  cirrhosis.  The  diagnostic  performance  results  (AUROC)
for  predicting  development  of  HCC  were  0.54,  0.58,  0.56  and
0.72  for  ARFI  in  the  liver,  ARFI  in  the  spleen,  the  FibroScan®
and  the  Fibrotest® [76]  respectively.
Assessment of  the efﬁcacy of antiviral
treatments
Several  publications  have  studied  the  utility  of  elastog-
raphy  techniques  to  assess  the  effectiveness  of  antiviral
and/or  anti-ﬁbrosing  treatment  by  monitoring  changes  in
liver  ‘‘elasticity’’  in  populations  of  patients  with  isolated
HCV  and  HBV  infection  [24,78,79].  Liver  elasticity  falls
after  antiviral  treatment  in  parallel  to  virological  response,
although  interpretation  of  these  reduced  values  is  difﬁcult
and  must  not  lead  to  the  patient’s  usual  treatment  being
changed.
Characterization of liver tumors
Only  a  few  authors  have  studied  the  utility  of  elastography
for  the  characterization  of  liver  tumors  and  the  differ-
entiation  between  benign  and  malignant  tumors  [80—86].
Table  5  summarizes  the  results,  conclusions  and  limitations
of  each  of  these  publications.  Results  vary  according  to  the
publication,  some  authors  reporting  that  it  is  possible  to
differentiate  benign  from  malignant  tumors  [80,82,83,85],
whereas  others  do  not  have  equivalent  results  [84,86].  The
differences  depend  on  a  large  number  of  factors:  the  propor-
tions  and  type  of  tumor  included  in  each  of  the  two  benign
and  malignant  groups,  whether  or  not  the  tumor  is  homo-
geneous,  the  composition  of  the  tumor,  the  regions  where
measurements  were  performed,  particularly  with  the  ARFI
technique  whose  region  of  interest  is  small.  Our  group  has
correlated  quantitative  ARFI  values  found  in  each  tumor
type  with  histological  ﬁndings  and  shown  that  large  varia-
tions  in  ARFI  measurements  can  be  seen  between  each  type
of  tumor  and  also  within  the  same  tumor  type  because  of
tissue  heterogeneity  [86].  These  variations  are  increasingly
pronounced  with  larger  heterogeneous  tumors.  Elastogra-
phy  measurements  are  very  dependent  on  the  composition
of  the  tissue  (necrosis,  hemorrhagic  change,  the  presence  of
a  colloid  component,  congestion,  sinus  distension,  peliosis,
S
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brosis,  etc.),  which  is  often  seen,  in  variable  proportions
n  benign  and  malignant  tumors  (Figs.  7  and  8).  Treatments
chemotherapy,  anti-angiogenesis  etc.)  can  also  change  the
tiffness  of  tumor  and  of  the  adjacent  liver.
uture prospects
ltrasound elastography and assessment of
iver ﬁbrosis
he  answer  to  the  question  of  whether  ultrasound  elastog-
aphy  techniques  are  sufﬁciently  effective  to  assess  liver
brosis  in  clinical  practice  in  patients  suffering  from  chronic
iver  disease  is  likely  to  be  positive  for  the  quantitative  tech-
iques.  It  is  clear  that  in  the  years  to  come,  the  use  of
lgorithms  combining  different  non-invasive  techniques  will
e  used  in  everyday  practice,  greatly  reducing  the  number
f  indications  for  LB.  The  elastography  techniques,  however,
lso  have  a  major  role  to  play  in  screening  for  chronic  liver
isease  in  ‘‘all-comers’’.  In  a  study  conducted  by  Roulot
t  al.  on  1190  people  over  45-years-old,  89  (7.5%)  had  a
ibroScan® liver  elasticity  value  of  over  8  kPa,  despite  nor-
al  blood  serum  markers,  and  a  cause  for  liver  disease  was
ound  in  43%  of  these  cases  [87].
In  terms  of  assessing  the  effectiveness  of  antiviral  treat-
ents  and  predicting  the  risk  of  complications  of  cirrhosis,
ltrasound  elastography  techniques  appear  to  be  promising,
lthough  further  studies  are  required  to  validate  them.
Alongside  these  ultrasound  elastography  techniques,  a
ew  technique,  elasto-MR,  is  also  being  developed.  This
RI  technique  has  the  advantage  of  performing  a  precise
orphological  analysis  of  the  liver  at  the  same  time  as
 measurement  of  ﬁbrosis,  and  therefore  contributes  to
he  investigations  into  the  cause  of  the  liver  disease  and
creening  for  HCC.  Promising  results  have  been  reported
rom  several  studies  in  chronic  viral  hepatitis  B  and  C  and
ASH.  Huwart  et  al.  (n  =  141)  showed  that  calculated  AUROC
alues  for  elasto-MR  (of  0.994  for  F  ≥  F2,  0.985  for  F  ≥  F3
nd  0.998  for  F  =  4  respectively)  were  signiﬁcantly  better
han  ultrasound  elastography  (0.837  for  F  ≥  F2;  0.906  for
 ≥  F3  and  for  F  =  0.93)  and  the  blood  serum  marker,  APRI
88]. In  view  of  the  small  number  of  patients  studied,  the
ength  of  the  examination  and  its  cost,  this  technique  cannot
t  present  be  used  routinely  in  clinical  practice.
ther applications
ltrasound  elastography  techniques  can  also  be  used  to
haracterize  tumors  and  monitor  local  treatments,  such  as
onitoring  thermal  ablation  treatments.
Elastography  techniques  can  be  of  assistance  in  guid-
ng  the  diagnosis  to  characterize  liver  tumors  when  they
re  combined  with  the  results  of  contrast  imaging  investi-
ations.  In  view  of  the  heterogeneity  of  both  benign  and
alignant  tumors,  it  is  not  currently  conceivable  to  envis-
ge  a  cut-off  value  to  characterize  all  types  of  liver  tumor.
imilarly,  it  appears  to  be  difﬁcult  to  establish  a  cut-off  to
ifferentiate  benign  from  malignant  because  of  the  over-
ap  of  elastography  values  between  benign  and  malignant
esions.  These  techniques,  however,  allow  us  to  better
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Table  5  Summaries  of  the  results,  conclusions  and  limitations  of  publications  on  elastography  to  characterize  liver  tumors.
References  Type  of  elastography  No.  of  tumours
Type  of  tumours
Results  Conclusions  Limitations
Kato  et  al.  [81]  Real  time  elastography
Qualitative  Elastography
n  =  55  21/22  HCC  are  classiﬁed  as
intermediary  hard  tumours
Real  time  elastography
differentiates  tumours  and
the  surrounding  tissue
No  quantitative  measurement
Malignant  T  24/28  metastases  are
classiﬁed  as  hard  tumours
HCC  and  metastases  can  be
differentiated  from  the  TES
score
Only angiomas  were  included
in  the  group  of  benign
tumours
HCC  (n  =  22) 1 angioma  is  classiﬁed
as  soft  tumour
HCC  appear  as  soft  or
intermediary  T  and
metastases  as  hard  T
No  correlation  with  histology
Metastases  (n  =  28)
CholangioK  (n  =  4)
Benign  T
Angiomas  (n  =  1)
Cho  et  al.  [82] ARFI
Qualitative  elastography
(n  =  60)
n =  60
Malignant  T
(n  =  43)
Mean  Velocity  (m/s)  There  is  a  signiﬁcant
difference  between  a  benign
T  (angiomas)  group  and  the
malignant  T
(metastases—CholangioK  +  HCC)
Only  angiomas  were  included
in  the  group  of  benign
tumours
Quantitative  elastography
(n  =  36)
HCC  (n  =  25)  Metastases  +  CholangioK
(n  =  8):
2.18  ±  0.96
The cut-off  value  to
differentiate  benign  from
malignant  is  2  m/s
No  correlation  with  histology
Metastases  (n  =  15)  HCC  (n  =  17):
2.5  ±  0.81
CholangioK  (n  =  3) Angiomas  (n  =  11):
1.51  ±  0.7Benign  T  (n  =  17)
Angiomas  (n  =  17)
Heide  et  al.  [84] ARFI
Quantitative  elastography
n =  62  Mean  velocity  (m/s) No  signiﬁcant  difference
between  benign  and
malignant  T  groups
No  correlation  with  histology
Malignant  T
(n  =  24)
Benign  tumours  group:
2.6  ±  0.97
Small number  of  adenomas
HCC  (n  =  5)  Angiomas:
2.36  ±  0.77
Metastases  (n  =  17)  FNH:
3.11  ±  0.93
U
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Table  5  (Continued)
References Type  of  elastography No.  of  tumours
Type  of  tumours
Results Conclusions  Limitations
CholangioK  (n  = 2) Adenomas:
2.23  ±  0.96
Benign  T  (n  =  38) Malignant  tumours
group:
2.9  ±  1.16
Angiomas  (n  =  13) HCC:
2.63  ±  1.09
FNH  (n  =  17) Metastases:
2.88  ±  1.16
Adenomas  (n  =  2) CholangioK:
3.78  ±  1.73
Davies  and
Koenen  [83]
ARFI
Quantitative  elastography
n =  45 Mean  velocity  (m/s) Signiﬁcant  difference
between  angiomas  and
metastases
Small  number  of  malignant
tumours
Malignant  T
(n =  10)
Angiomas:
1.35 ±  0.48
The cut-off  value  to
differentiate  benign
(Angiomas)  from  malignant
(Metastases)  was  2.5  m/s
Only  angiomas  were  included
in  the  benign  T  group
Metastases  (n  =  10) Metastases:
4.18  ±  0.71
No  correlation  with  histology
Benign  T  (n  =  35)
Angiomas  (n  =  35)
Shuang  ming
et  al.  [80]
ARFI
Quantitative  elastography
n =  128  Mean  velocity  (m/s)  Signiﬁcant  difference
between  angiomas  and
metastases
Small  number  of  FNH  and
adenomas
Malignant  T
(n =  68)
Benign  tumours  group:
1.47  ±  0.53
The cut-off  value  to
differentiate  between  benign
and  malignant  was  2.22  m/s
No  correlation  with  histology
HCC  (n  =  31) Malignant  tumours  group:
3.16  ±  0.80Metastases  (n  =  30)
CholangioK  (n  = 7)
Benign  T  (n  =  60)
Angioma  (n  =  28)
FNH  (n  =  7)
Adenoma  (n  =  1)
Others  (n  =  25)
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Table  5  (Continued)
References  Type  of  elastography  No.  of  tumours
Type  of  tumours
Results  Conclusions  Limitations
Guibal  et  al.  [85] Shear  Wave  elastography  n  =  139  Mean  elasticity  (kPa)  Signiﬁcant  difference
between  the  benign  and
malignant  T  groups
Limited  number  of  some
lesions
Qualitative  elastography  Malignant  T  Benign  tumours  group:
18.53  ±  13.5
SWE can  differentiate
adenomas  from  FNH
No  details  about  number  of
different  sub-types  of
adenomasQuantitative  elastography HCC  (n  =  26)  Angiomas:
13.8  ±  5.5
SWE can  differentiate  HCC
and  cholangioK
CholangioK:  (n  =  7)  FNH:
33  ±  14.7
The  most  discriminating
cut-off  values  to
differentiate  HCC  from
cholangioK  was  >  27.5  kPa
Metastases:  (n  =  53)  Adenomas:
9.4  ±  4.3
Benign  T  Malignant  tumours
group:
26.9  ±  18.8
Angiomas:  (n  =  22)  HCC:
14.86  ±  10
FNH:  (n  =  16)  Metastases:
28.8  ±  16
Adenomas:  (n  =  10)  CholangioK:
56.9  ±  25.6
Others
Frulio  et  al.  [86] ARFI
Quantitative  elastography
n =  79
Malignant  T
Mean  velocity  (m/s)  No  signiﬁcant  difference
between  benign  and
malignant  T  groups
Small  number  of  some  lesions
HCC  (n  =  24) Benign  tumours  group Large  tissue  heterogeneity
for  the  same  type  of  tumour
and  between  tumour  types
No  cholangiocarcinomas
Metastases  (n  =  12)  Angiomas:  2.14  ±  0.49
Benign  T  FNH:  3.14  ±  0.63
Angiomas  (n  =  15)  Adenomas:  1.9  ±  0.86
FNH  (n  =  19)  Malignant  tumours  group
Adenomas  (n  =  9)  CHC:  2.4  ±  1.01
Metastases:  3.0  ±  1.36
T: tumour; cholangioK: cholangicarcinoma; HCC: hepatocellular carcinoma; ARFI: Acoustic Radiation Force Impulse Imaging.
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Figure 7. Correlation between ARFI measurements, macroscopic and microscopic appearance: example of FNH: a: ultrasound investi-
gation: the tumor (60 mm) is heterogeneous and hyperechogenic centrally and isogenic peripherally. The median ARFI value is 3.6 m/s;
b: macroscopic: non-encapsulated, multi-modular tumor with a centr
hepatocyte nodules (N) are separated by dense ﬁbrous tissue (asterisk).
Figure 8. Shear wave elastography: example of a cholangiocar-
cinoma [85]. SWE mode color mapping shows a hard (red) lesion
in a ‘‘soft’’ (blue) liver. Mean elasticity obtained by the Q-box is
53.5 kPa (±20 kPa). The lesion is hypoechogenic in B mode.
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pal ﬁbrous scar (asterisk); c: microscopy (Masson trichrome): the
nderstand  the  relationships  between  tissue  composition
nd  ‘‘tissue  elasticity’’.
In  terms  of  monitoring  thermal  ablation  therapy  treat-
ents,  Kolokythas  et  al.  have  shown  in  vivo  that  the  ablation
herapy  region  was  associated  with  a  rise  in  stiffness,  which
ould  be  clearly  differentiated  from  the  untreated  surround-
ng  tissue  [89]. Similarly,  Van  Vledder  et  al.  have  shown
oth  in  animals  and  in  human  beings  that  the  boundaries
f  the  ablation  therapy  sites  could  be  identiﬁed  better  by
lastography  mapping  than  with  B  mode  imaging.  They  also
howed  that  elastography  was  straightforward  to  perform
er  procedure  and  that  the  volume  treated  identiﬁed  by
lastography  correlated  well  with  the  volume  found  on  the
epatectomy  specimen  [90]. Elastography  techniques  seem
o  be  a  promising  tool  in  the  control  and  real  time  follow  up
f  liver  tumor  thermal  ablation  as  their  elasticity  increases
ith  the  increasing  treated  volume.
onclusion
o  conclude,  elastography  imaging  in  a novel  imaging  tech-
ique  for  assessing  human  soft  tissue  mechanical  properties,
hich  is  currently  under  clinical  evaluation  for  several
rgans,  such  as  breast,  thyroid,  prostate,  kidney,  vessels,
arotids,  liver  and  other  organs.
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For  liver  applications,  ﬁbrosis  staging  is  the  main  diagnos-
ic  indication  and  shear  wave  based  techniques  have  been
alidated  clinically  in  a  ﬁrst  and  second  intention  to  diagno-
is  for  ﬁbrosis  staging  in  chronic  viral  hepatitis  C,  replacing
he  invasive  conventional  liver  biopsy,  which  was  up  to  now
he  gold  standard.  However  there  are  many  other  promising
ndications  for  elastography  that  are  currently  under  clinical
valuation,  such  as  hepatic  tumor  characterization,  pre-
icting  cirrhosis-related  complications,  monitoring  antiviral
reatments  in  chronic  viral  liver  disease,  and  monitoring
ocal  treatments  etc.. .  .  that  might  play  a  major  role  in  the
anagement  of  hepatic  diseases.
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